Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.45)
# 663
Out of 5,182 analysts
53
Total ratings
39.02%
Success rate
4.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Overweight | n/a | $13.15 | - | 1 | Mar 24, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $23.59 | +213.69% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $5.84 | - | 1 | Oct 16, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $16.12 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $46.37 | - | 1 | Jul 17, 2025 | |
| RNA Atrium Therapeutics | Reiterates: Overweight | $96 | $13.43 | +614.82% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $10.64 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $10.79 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $25.18 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $21.67 | -39.96% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.83 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $51.63 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $96.91 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.16 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.98 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.16 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $187.06 | +56.10% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $423.92 | -12.72% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.90 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.79 | - | 1 | May 30, 2017 |
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $13.15
Upside: -
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $23.59
Upside: +213.69%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $5.84
Upside: -
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $16.12
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $46.37
Upside: -
Atrium Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $13.43
Upside: +614.82%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.64
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.79
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $25.18
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $21.67
Upside: -39.96%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.83
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $51.63
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $96.91
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.16
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.98
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.16
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $187.06
Upside: +56.10%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $423.92
Upside: -12.72%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.90
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.79
Upside: -